This preprint reports that participants with Long COVID exhibit a persistent hypercoagulable plasma phenotype when assessed by thromboelastography (TEG). The study analyzed both whole blood and platelet-poor plasma (PPP) from control (n=19) and Long COVID (n=20) participants. Long COVID samples showed shortened R, K and TMRTG and elevated alpha-angle and MRTG, while maximal amplitude (MA) and total thrombus generation (TTG) were unchanged. These findings indicate altered clotting kinetics—faster initiation and propagation of clot formation—without an increase in maximal clot strength.
The persistence of the hypercoagulable signature in PPP implicates soluble plasma constituents as contributors to the phenotype, rather than whole-blood cellular content alone. The authors highlight that the TEG profile reflects altered coagulation dynamics in Long COVID but does not indicate increased clot firmness by MA or TTG measures.
The study compared samples from control (n=19) and Long COVID (n=20) participants. Whole-blood and PPP samples were assessed with TEG. FMCs—referred to in the paper as fibrinaloid microclot complexes (FMCs)—were quantified using imaging flow cytometry of Thioflavin-T (ThT)-stained PPP across three processing states: undiluted PPP, 10X diluted PPP, and resuspended PPP pellets after centrifugation.
The resuspended pellets were stained separately with CD62P-PE antibody to label platelet-derived material and with Hoechst 33342 to mark nuclear (leukocyte) material. Co-staining of ThT with CellMask Red enabled confocal microscopy of membranes, and combinations including ThT with myeloperoxidase (MPO), and ThT with Congo Red and Hoechst were used for fluorescence and polarized microscopy. Whole-blood smears were also imaged by scanning electron microscopy (SEM).
Ethical clearance was granted by the Health Research Ethics Council (HREC) of Stellenbosch University, and samples were obtained from an anonymized biorepository with informed consent. The authors note that the manuscript is a preprint and has not been peer reviewed.
Using Thioflavin-T staining and imaging flow cytometry, the investigators found a significant increase in ThT-positive FMCs in the Long COVID group across undiluted PPP, diluted PPP, and resuspended pellet preparations. FMC counts were processing-sensitive: a notable ThT-positive population remained in the supernatant after centrifugation, indicating heterogeneity in the density and sedimentation behavior of FMCs.
This observation suggests that some amyloid-containing FMCs are of lower density and remain in the plasma fraction after standard centrifugation, whereas other FMC species pellet under the same conditions. The presence of ThT-positive material in multiple processing states supports a complex and heterogeneous FMC burden in Long COVID plasma.
Across the probe panel and imaging methods, three broad FMC-associated populations were identified with distinct morphologies and size domains: events containing leukocyte-derived material, events containing platelet-derived material, and ThT-positive amyloid-dominated events. Quantitatively, leukocyte-associated material was the most abundant, followed by platelet-derived material, with ThT-only FMCs being the least abundant numerically.
Confocal, fluorescence, and polarized microscopy of co-stained samples demonstrated heterogeneity within FMCs. Events were observed that were positive for combinations of probes including ThT, CellMask Red (membrane marker), Hoechst (nuclear), MPO (a leukocyte marker), and Congo Red (an amyloid dye). SEM imaging of whole-blood smears provided complementary morphological detail.
The study reports that platelet-derived material in PPP was significantly elevated in the Long COVID cohort compared with controls, whereas nuclear (leukocyte) material was not significantly different between groups. The elevated platelet debris in PPP is interpreted by the authors as indicative of ongoing or persistent platelet activity in Long COVID.
Importantly, the investigators identified a distinct subset of membrane-free, ThT-only events—amyloid-positive FMCs lacking associated membrane markers. The existence of these membrane-free amyloid events, together with Congo Red positivity in some FMCs, supports the conclusion that an amyloid-dominated FMC population exists in PPP from people with Long COVID.
The combined TEG and imaging data led the authors to conclude that Long COVID plasma is characterised by persistent hypercoagulability and an increased burden of ThT-positive FMCs. Although ThT-positive FMCs were numerically minor relative to leukocyte- and platelet-associated aggregates, they were morphologically distinct and included membrane-free amyloid forms.
Because the hypercoagulable phenotype persisted in PPP, the authors emphasize the role of soluble plasma constituents in driving altered clotting kinetics. The increased platelet-derived debris suggests ongoing platelet activation or turnover, which may contribute to coagulopathy and microvascular pathology reported in Long COVID. Confirmation of amyloid content by Congo Red further supports the amyloid nature of at least a subset of FMCs.
The manuscript is a clinical preprint and has not undergone peer review; the authors explicitly state this status. Ethical approval was provided by Stellenbosch University HREC (project ID reported in the source), and samples were used with informed consent from a university biorepository. The authors report that all data produced in the study are available upon reasonable request.
Details such as longitudinal clinical correlations, functional impact of the identified FMC subtypes, and therapeutic implications were not reported in the source abstract and would require peer-reviewed publication and further study for clinical translation.